LTRN Quick Ratio | Lantern Pharma Inc.

Lantern Pharma Inc. Quick Ratio

The quick ratio is a stricter test of whether a company can pay the bills due within a year, counting only assets that are already cash or close to it. It is cash, marketable securities and receivables divided by current liabilities, shown as a multiple, with both amounts in the table. It is the current ratio with inventory and other assets that take longer to turn into cash removed, so it is never higher than the current ratio. A company that does not report one of the inputs has no point for that date rather than an estimated one. Quarterly points use quarter-end balances; annual points use fiscal-year-end balances.

Lantern Pharma Inc. quick ratio for the quarter ending 2026-06-30 was 1.7, a 47.69% decline year-over-year.
Lantern Pharma Inc. quick ratio for the quarter ending 2026-03-31 was 1.67, a 63.62% decline year-over-year.
Lantern Pharma Inc. quick ratio for the quarter ending 2025-12-31 was 2.25, a 59.45% decline year-over-year.
Lantern Pharma Inc. quick ratio for the quarter ending 2025-09-30 was 3.06, a 60.72% decline year-over-year.
Lantern Pharma Inc. quick ratio for fiscal 2025 was 2.25, a 59.45% decline from fiscal 2024.
Lantern Pharma Inc. quick ratio for fiscal 2024 was 5.54, a 64.05% decline from fiscal 2023.
Lantern Pharma Inc. quick ratio for fiscal 2023 was 15.42, a 21.82% decline from fiscal 2022.
Lantern Pharma Inc. quick ratio for fiscal 2022 was 19.72, a 35.12% decline from fiscal 2021.

Available history: 2019-12-31 to 2026-06-30
Data captured: 2026-06-30

Historical Quick Ratio

Date	Quick Ratio	Quick assets	Current liabilities
2026-06-30	1.7	$7.36M	$4.32M
2026-03-31	1.67	$6.32M	$3.78M
2025-12-31	2.25	$10.12M	$4.5M
2025-09-30	3.06	$12.36M	$4.04M
2025-06-30	3.26	$15.9M	$4.88M
2025-03-31	4.6	$19.72M	$4.29M
2024-12-31	5.54	$24.01M	$4.33M
2024-09-30	7.79	$28.05M	$3.6M
2024-06-30	7.23	$33.26M	$4.6M
2024-03-31	9.7	$38.36M	$3.95M
2023-12-31	15.42	$41.3M	$2.68M
2023-09-30	19.94	$44.93M	$2.25M
2023-06-30	15.9	$47.95M	$3.02M
2023-03-31	18.45	$51.54M	$2.79M
2022-12-31	19.72	$55.2M	$2.8M
2022-09-30	18.42	$57.83M	$3.14M
2022-06-30	11.72	$62.15M	$5.3M
2022-03-31	21.22	$65.22M	$3.07M
2021-12-31	30.4	$70.73M	$2.33M
2021-09-30	41.35	$73.83M	$1.79M
2021-06-30	29.61	$79.59M	$2.69M
2021-03-31	122.45	$81.37M	$664,533.00
2020-12-31	34.81	$19.23M	$552,339.00
2020-09-30	25.54	$20.8M	$814,557.00
2020-06-30	10.45	$23.8M	$2.28M
2019-12-31	2.52	$1.23M	$489,292.00

Annual Quick Ratio

Date	Quick Ratio	Quick assets	Current liabilities
2025-12-31	2.25	$10.12M	$4.5M
2024-12-31	5.54	$24.01M	$4.33M
2023-12-31	15.42	$41.3M	$2.68M
2022-12-31	19.72	$55.2M	$2.8M
2021-12-31	30.4	$70.73M	$2.33M
2020-12-31	34.81	$19.23M	$552,339.00
2019-12-31	2.52	$1.23M	$489,292.00

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Citius Pharmaceuticals, Inc. (CTXR)	United States	$0.016B	-133.06
Anebulo Pharmaceuticals, Inc. (ANEB)	United States	$0.015B
Korsana Biosciences, Inc. (CYCN)	United States	$0.016B
ACTUATE THERAPEUTICS, INC. (ACTU)	United States	$0.015B
Tvardi Therapeutics, Inc. (TVRD)	United States	$0.014B
Vyome Holdings, Inc (HIND)	United States	$0.014B	-1.38
BullFrog AI Holdings, Inc. (BFRG)	United States	$0.014B
Pasithea Therapeutics Corp. (KTTA)	United States	$0.017B	-0.81
Allarity Therapeutics, Inc. (ALLR)	United States	$0.017B	-1.66
LISATA THERAPEUTICS, INC. (LSTA)	United States	$0.014B	-2.13